三生制药集团
Location: China
Employees: 5001-10000
Total raised: $712M
Founded date: 1993
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.05.2015 | IPO | $712M | - |
Mentions in press and media 18
| Date | Title | Description |
| 28.08.2026 | Tigermed Announces 2026 Interim Results | HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, annou... |
| 02.03.2026 | XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy | SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with i... |
| 04.11.2025 | Pfizer tops estimates, raises profit guidance even as sales fall | Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell. The pharmaceutical giant now expects its full-year adjusted profit to come ... |
| 05.08.2025 | Pfizer raises 2025 profit forecast as cost-cutting program gains traction | Pfizer raises 2025 profit forecast as cost-cutting program gains traction By Bhanvi Satija and Michael ErmanAugust 5, 20254:40 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link SummaryCompanies Qu... |
| 05.08.2025 | Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results | Pfizer hiked its full-year adjusted profit guidance on cost cuts and its strong business performance this year. The company also reported second-quarter results that topped Wall Street’s estimates for the period. The results come as Pfizer ... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong. In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 29.05.2025 | China's biotech having its 'DeepSeek' moment amid big pharma M&A spree: ORI Capital founder | Global pharma giant Pfizer’s recent announcement of a record $1.25-billion upfront payment to buy the exclusive global license of Hong Kong-listed 3SBio’s cancer drug underscores the growing momentum displayed by big pharma towards investme... |
| 01.11.2023 | CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China | CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainland China. CStone to retain the rights to nofazinlimab outside mainland China. This ... |
| 25.08.2023 | 3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced | HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately RMB3,783.8 million, up 22.3% on a yearly ba... |
| 22.03.2023 | 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% | HONG KONG, March 21, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical products posted robust growth, hair health business achiev... |
Show more